Dr. Daniel F. Smith CV
Learn More About This Board-Certified Dermatologist Serving the Little Rock Area
Business Address
| Private Practice, Dermatology Dermatology Group of Arkansas Medical Towers 1, Suite 690 9601 Baptist Health Drive Little Rock, Arkansas 72205 Telephone 501-227-8422 FAX 501-537-1079 |
2003-present |
| Texarkana Dermatology Associates 4101 Richmond Meadows Texarkana, TX 75503 |
2001-2003 |
| White Hall Family Practice 106 Cooper · White Hall, AR 71602 |
1997-1998 |
| Pine Bluff Medical Practice 4010 Mulberry Street Pine Bluff, Arkansas 71603 |
1996-1997 |
Education
| Bachelor of Science in Business Administration University of Arkansas at Fayetteville Fayettevi lle, Arkansas |
1984-1988 |
| Master of Business Administration University of Arkansas at Fayetteville Fayetteville, Arkansas |
1988-1989 |
| Doctor of Medicine University of Arkansas Medical Sciences Little Rock, Arkansas |
1992-1996 |
| Dermatology Residency University of South Florida. Tampa, Florida |
1998-2001 |
Licensure
Arkansas, License #E-1486
Te xas, License #L1754
Certifications
| Board Certified in Dermatology | October 2001 |
Honors and Activities
| Alpha Omega Alpha | 1995 |
| Barton Foundation Scholarship | 1995 |
| Medical College Physician’s Group Scholarship | 1994 |
| Cardiopulmonary Resuscitation & Emergency Care Instructor | 1993,1995 |
| Advanced Trauma Life Support | 1997 |
| Arkansas Student Government Senator | 1988 |
| Sigma Alpha Epsilon Fraternity | |
| Dean’s List (Top 10%) | 1988-1989 |
| President’s List (4.0 GPA) | 1987-1988 |
| Omicron Delta Kappa, National Leadership Fraternity | |
| Beta Gamma Sigma, Academic/Leadership Business Fraternity for Top 5% of Class |
Professional Affiliations
American Medical Association
Research Training
| Human Participant Protections Education for Research Teams | April 17, 2006 |
| National Cancer Institute HIH Online Course www.cancer.gov |
Meet Your Doctors
Meet Your Doctors
Meet Your Doctors
Research Experience
| The Efficacy of Gold-Weight Treatment for Lagophthalmos, Charles Rice, M.D., Dept. of Ophthalmo logy, UAMS | |
| “A Multi-Center Phase 3, In vestiga tor Blind Clinical Trial to Assess the Safety and Efficac;y of a Topical Cream Applied Once Daily 3 Days per Week in I or 2 Courses of Treatment of Actinic Keratosis on the Head .” | 2003 |
| “A Double-Blind Placebo Controlled Study of the Recurrence and Re-treatment of Actinic Keratosis after Treatment with a Topical Cream.” | 2003 |
| “A Multi-Center, Open Label, Long-Tenn Safety Trial ofa Topical Gel in the Treatment of Acne Vulgaris” | |
| “Phase III Vehicle-controlled, Double-blind study to assess the Safety and Efficacy of a Topical Cream for the Treatment ofMolluscum Contagiosum in Ped iatri c Patients” | |
| “Phase II, Multicenter, Double-blind , Randomized, Dose-ranging Evaluation of the Efficacy of a Topical Gel Following Repeated Topical Application in Subjects with Acne Vulgaris” | |
| “A Phase 3, Multicenter, Randomized, Double Blind, Vehicle Controlled Study of the Safety and Efficacy of a Foam, in the Treatment of Adolescent and Pediatric Subjects with Mild to Moderate Atopic Dermatitis.” | |
| “A randomized, investigator blinded, active-co ntrolled, parallel group study to compare the efficacy and safety of 6-week treatment with a new pediatric formulation versus 6-week treatment with a pediatric suspension in children with Tinea Capitis” | |
| “Ra ndomi zed, Double-B lind, Placebo-Controlled Phase III Study of an Extend ed-Release Formulation of an antibiotic for the Treatment of the Inflammatory Lesions of Acne Vulgaris” | |
| “An Open-Label Safety Study of a New Formula tio n of an antibiotic for the Treatment of Moderate to Severe .Acne” | |
| “A Phase 3, Multicenter, Randomized, Double Blind, _Vehicle Cont rolled Study of the Safety and Efficacy of a Foam, in the Treatment of Adolescent and Pediatric Subjects with Mild to Moderate Atopic Dermatitis.” | |
| “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Effects of Modified Release Capsules Administ ered Once Daily for the Treatment of Rosacea.” | |
| “A multicentre, randomis ed, double blind; placebo controlled phase III study of a subcutaneously administered biologic in the treatment and re-treatment of subjects with moderate to severe plaque psoriasis.” | |
| “Placebo-controlled Multicenter Study with a biologic to Determine Safety and Efficacy-in Pediatric Subjects with Plaque Psoriasisi s (PEDS)” | |
| “A Phase 3, Multi-Center Study of the Efficacy and Safety of Long-Term Biologic Treatment in Subjec ts with Moderate to Severe Chronic Plaque Psoriasis.” | |
| “A randomized, investigator blinded, active-controlled, parallel group study to compare the efficacy and safety of 6-week treatment with a new pediatric formula versus 6-week treatment with an approved pediatric suspension in children wjth Tinea Capitis” | |
| “A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year after Completioh of the 1473-IMIQ Study (IND #49,480).” | |
| “A Randomized, Double-Blind, Placebo-Controlled, Safety and Tolera bility Study of a biologic in Subjects with Chronic Plaque Psoriasis Requiring Systemic Therapy.” | |
| “An Open-label Extension Study to Evaluate the Safety ofEt ercept in Pediatric Subjects with Plaque Psoriasis” | |
| “A Randomized, evaluator blinded, vehicle-controlled multi-center study of the safety and efficacy of 4% Trad ename Fluorouracil) cream versus it s vehicle cream versus Efudex cream in the Treatment of Actinic Keratosis” | |
| “A Phase II, Multi-Center, Randomized, Evaluator-Blind, Vehicle Controlled, 6-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of Clindaben (1/2.5), Clindamycin (1%), and Benzoyl Peroxide (2.5%) Gels in the Treatment of Acne Vulgaris.” | |
| “Raptiva Epidemiologic Srudy of Psoriasis Outcomes and Safety Events (RESPONSE) in Patients with Chronic Moderate to Severe Plaque Psoriasis” | |
| “Phase 2/3 Study: A Multicenter Open Label Continuation Study in Moderate to Severe Plaque Psoriasis Subjects who completed a Preceding Psoriasis Clinical Study with Adalimumab” | |
| “A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and Efficacy of l% and 2% Nanocrystalline Silver Cream (NPI 32101) Applied Twice Daily in Pediatric and Adolescent Subjects with Mild to Moderate Atopic Dermatitis” | |
| “An Open-Label, Treatment Continuation Study Of2% Nanocrystalline Silver Cream (NPI 32101) Applied Twice Daily In Children with Atopic Dermatitis Who Previously Completed A Doub le-Blind, Placebo-Controlled Study OfNPI 32101” | |
| “A Open-label;multi-center, uncontrolled, single-group assignment, long-t erm safety study of 4% Tradename (Fluorouracil) cream in subjects with Actinic Keratosis (who participated in the Phase III studies)” | |
| “Observational Post-Marketing Safety Surveillance Registry ofEnbrel (entanercept) for the Treatment of Psoriasis” | |
| “A multi-center, randomized, double-blind, parallel-group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel vehicle in subjects with acne vulgaris” | |
| “An open-label extension study to evaluate the safety of entercept in pediatric subjects with plaque psoriasis FEDS” | |
| “A phase III, multi-center, randomized, doubl e-bli nd, vehicle-controlled, 4-arm, parallel group comparison study comparing 1he efficacy and safety of clindaben ½.5), Clindaben vehicle, clindarnycin (1%), and benzoyl Peroxide (2.5%) Gels in the treatment of moderate to severe acne vulgaris” | |
| “Phannacokinetics and Pharmacodynarnics of calcitriol following twice daily application of calcitriol 3ug/g ointment under conitions of maximal use in adolescents with plaque psoriasis” | |
| “A Phase 3, multicenter, randomized, double-blind, placebo controlled trial eva luating the efficacy and safety of CNTO 1275 in the treatment of subjects with moderate to severe plaque-type psoriasis” | |
| “Raptiva Epidemiologic study of psoriasis outcomes and safety events (RESPONSE) in patients with chronic moderate to severe plaque psorisis” | |
| “A randomized, double-blind, parallel-group, 4-arm, 12-week study to evaluate the safety and efficacy of topically applied CTAO18 vs. vehicle for the treatment of adult subjects with chroriic plaque psoriasis” |
Contact Us Today
Contact the Dermatology Group of Arkansas today. Call 501-227-8422.
